Literature DB >> 24495460

Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice.

Rachel J Donahue1, John W Muschamp1, Scott J Russo2, Eric J Nestler2, William A Carlezon3.   

Abstract

BACKGROUND: Chronic social defeat stress (CSDS) produces persistent behavioral adaptations in mice. In many behavioral assays, it can be difficult to determine if these adaptations reflect core signs of depression. We designed studies to characterize the effects of CSDS on sensitivity to reward because anhedonia (reduced sensitivity to reward) is a defining characteristic of depressive disorders in humans. We also examined the effects of striatal ΔFosB overexpression and the N-methyl-D-aspartate receptor antagonist ketamine, both of which promote resilience, on CSDS-induced alterations in reward function and social interaction.
METHODS: Intracranial self-stimulation (ICSS) was used to quantify CSDS-induced changes in reward function. Mice were implanted with lateral hypothalamic electrodes, and ICSS thresholds were measured after each of 10 daily CSDS sessions and during a 5-day recovery period. We also examined if acute intraperitoneal administration of ketamine (2.5-20 mg/kg) reverses CSDS-induced effects on reward or, in separate mice, social interaction.
RESULTS: ICSS thresholds were increased by CSDS, indicating decreases in the rewarding impact of lateral hypothalamic stimulation (anhedonia). This effect was attenuated in mice overexpressing ∆FosB in striatum, consistent with pro-resilient actions of this transcription factor. High, but not low, doses of ketamine administered after completion of the CSDS regimen attenuated social avoidance in defeated mice, although this effect was transient. Ketamine did not block CSDS-induced anhedonia in the ICSS test.
CONCLUSIONS: This study found that CSDS triggers persistent anhedonia and confirms that ΔFosB overexpression produces stress resilience. The findings of this study also indicate that acute administration of ketamine fails to attenuate CSDS-induced anhedonia despite reducing other depression-related behavioral abnormalities.
Copyright © 2014 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anhedonia; antidepressant; defeat; intracranial self-stimulation (ICSS); ketamine; social interaction; stress

Mesh:

Substances:

Year:  2014        PMID: 24495460      PMCID: PMC4087093          DOI: 10.1016/j.biopsych.2013.12.014

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  90 in total

Review 1.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

2.  DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.

Authors:  Vincent Vialou; Alfred J Robison; Quincey C Laplant; Herbert E Covington; David M Dietz; Yoshinori N Ohnishi; Ezekiell Mouzon; Augustus J Rush; Emily L Watts; Deanna L Wallace; Sergio D Iñiguez; Yoko H Ohnishi; Michel A Steiner; Brandon L Warren; Vaishnav Krishnan; Carlos A Bolaños; Rachael L Neve; Subroto Ghose; Olivier Berton; Carol A Tamminga; Eric J Nestler
Journal:  Nat Neurosci       Date:  2010-05-16       Impact factor: 24.884

3.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

4.  Serial infusions of low-dose ketamine for major depression.

Authors:  Keith G Rasmussen; Timothy W Lineberry; Christine W Galardy; Simon Kung; Maria I Lapid; Brian A Palmer; Matthew J Ritter; Kathryn M Schak; Christopher L Sola; Allison J Hanson; Mark A Frye
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

5.  Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study.

Authors:  Celia J A Morgan; Ali Mofeez; Brigita Brandner; Lesley Bromley; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

6.  Association of different adverse life events with distinct patterns of depressive symptoms.

Authors:  Matthew C Keller; Michael C Neale; Kenneth S Kendler
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

7.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice.

Authors:  Sarah Dubreucq; Isabelle Matias; Pierre Cardinal; Martin Häring; Beat Lutz; Giovanni Marsicano; Francis Chaouloff
Journal:  Neuropsychopharmacology       Date:  2012-03-21       Impact factor: 7.853

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  87 in total

1.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

2.  VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.

Authors:  Cheng Jiang; Wei-Jye Lin; Benoit Labonté; Carol A Tamminga; Gustavo Turecki; Eric J Nestler; Scott J Russo; Stephen R Salton
Journal:  Neuropsychopharmacology       Date:  2018-11-20       Impact factor: 7.853

Review 3.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

4.  Bidirectional relationship between alcohol intake and sensitivity to social defeat: association with Tacr1 and Avp expression.

Authors:  Britta S Nelson; Michelle K Sequeira; Jesse R Schank
Journal:  Addict Biol       Date:  2017-02-01       Impact factor: 4.280

5.  Sex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability.

Authors:  Katherine N Wright; Mohamed Kabbaj
Journal:  Curr Opin Behav Sci       Date:  2018-03-02

6.  Ketamine beyond anesthesia: Antidepressant effects and abuse potential.

Authors:  Keith A Trujillo; Sergio D Iñiguez
Journal:  Behav Brain Res       Date:  2020-07-31       Impact factor: 3.332

Review 7.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

8.  Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2014-05-06       Impact factor: 13.382

Review 9.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

10.  Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles.

Authors:  Rosemary C Bagot; Hannah M Cates; Immanuel Purushothaman; Vincent Vialou; Elizabeth A Heller; Lynn Yieh; Benoit LaBonté; Catherine J Peña; Li Shen; Gayle M Wittenberg; Eric J Nestler
Journal:  Biol Psychiatry       Date:  2016-06-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.